FI120670B - Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö - Google Patents

Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö Download PDF

Info

Publication number
FI120670B
FI120670B FI964033A FI964033A FI120670B FI 120670 B FI120670 B FI 120670B FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 120670 B FI120670 B FI 120670B
Authority
FI
Finland
Prior art keywords
cells
formulated
medicament
sertoli
transplantation
Prior art date
Application number
FI964033A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964033A (fi
FI964033A0 (fi
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of FI964033A0 publication Critical patent/FI964033A0/fi
Publication of FI964033A publication Critical patent/FI964033A/fi
Application granted granted Critical
Publication of FI120670B publication Critical patent/FI120670B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI964033A 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö FI120670B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
US21169594 1994-04-13
US9504565 1995-04-13
PCT/US1995/004565 WO1995028167A1 (fr) 1994-04-13 1995-04-13 Procedes de traitement de maladies a l'aide de cellules de sertoli et des allogreffes ou xenogreffes

Publications (3)

Publication Number Publication Date
FI964033A0 FI964033A0 (fi) 1996-10-08
FI964033A FI964033A (fi) 1996-12-12
FI120670B true FI120670B (fi) 2010-01-29

Family

ID=22787974

Family Applications (2)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (fi) 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Country Status (12)

Country Link
US (3) US5725854A (fr)
EP (1) EP0755258B1 (fr)
JP (1) JPH09512015A (fr)
AT (1) ATE212230T1 (fr)
AU (1) AU715177B2 (fr)
CA (1) CA2187803C (fr)
DE (1) DE69525151T2 (fr)
DK (1) DK0755258T3 (fr)
ES (1) ES2169128T3 (fr)
FI (2) FI120670B (fr)
NO (1) NO320713B1 (fr)
WO (1) WO1995028167A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
US5830460A (en) 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
EP0814819B1 (fr) * 1995-03-13 2004-07-14 University Of South Florida Cellules de sertoli employees comme facilitateur de transplantation cellulaire
WO1996033264A1 (fr) * 1995-04-20 1996-10-24 University Of South Florida Agregat de cellules de sertoli purifiees et isolees
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
CA2317115A1 (fr) * 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Utilisation de cellules epitheliales retiniennes pigmentees pour la creation d'un site d'acception immunitaire
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
JP5323293B2 (ja) * 1998-11-06 2013-10-23 セルトーリ テクノロジーズ エルエルシー 生物学的因子の生産および遺伝的に改変されたセルトーリ細胞を用いる免疫学的特権環境の創製
SI20847B (sl) * 1998-12-15 2009-04-30 Univ Mexico Nacional Autonoma Postopek in naprava za zaščito biološkega vsadka
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DK1248640T3 (da) 2000-01-20 2007-02-12 Diabcell Pty Ltd Xenotransplantation af svineöer og deres fremstilling
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
CA2421036A1 (fr) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Amelioration d'un procede de fabrication d'organes bioartificiels en feuille fine
JP4866535B2 (ja) 2001-05-11 2012-02-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 動物で用いるに適した免疫調節用デバイス
WO2003027270A1 (fr) * 2001-09-28 2003-04-03 Diabcell Pty Limited Croissance d'une matiere pour xenotransplant dans une culture
CN1646162A (zh) * 2002-02-22 2005-07-27 普罗菲医疗公司 组织因子的抑制剂或拮抗剂的用途
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
CA2529573A1 (fr) * 2003-06-24 2004-12-29 Diabcell Pty Limited Ilots porcins cultives avec des cellules de sertoli porcines pour la xenotransplantation
CA2531022C (fr) * 2003-07-03 2014-09-09 Jannette Dufour Compositions contenant des cellules de sertoli et des cellules myoides et leurs utilisations dans des greffes cellulaires
US8263068B2 (en) * 2004-04-29 2012-09-11 Washington State University Research Foundation Modified cells expressing a protein that modulates activity of bHLH proteins, and uses thereof
EP1781205A4 (fr) 2004-07-29 2011-03-30 Univ Miami Dispositif hybride pour therapies cellulaires
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
WO2007089572A2 (fr) * 2006-01-26 2007-08-09 John Constance M Cultures de cellules de sertoli humaines primaires proliférantes et leurs applications
EP2046351A2 (fr) * 2006-07-28 2009-04-15 Sertocell Biotechnology (US) Corp. Cellules de sertoli adultes et utilisation de celles-ci
US9161901B2 (en) 2008-02-21 2015-10-20 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
PL2470228T3 (pl) 2009-08-28 2018-03-30 Sernova Corporation Sposoby i urządzenia do przeszczepiania komórek
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
EP3697469A4 (fr) 2017-10-17 2021-09-22 The Methodist Hospital System Dispositifs d'administration
EP3962505A1 (fr) 2019-05-01 2022-03-09 Sernova Corporation Méthodes de traitement du diabète à l'aide de dispositifs pour transplantation cellulaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
US5843430A (en) 1998-12-01
FI120696B (fi) 2010-01-29
FI964033A (fi) 1996-12-12
CA2187803A1 (fr) 1995-10-26
ATE212230T1 (de) 2002-02-15
EP0755258A1 (fr) 1997-01-29
FI20085733A (fi) 2008-07-18
EP0755258B1 (fr) 2002-01-23
US5725854A (en) 1998-03-10
NO964342D0 (no) 1996-10-11
NO320713B1 (no) 2006-01-23
AU2289395A (en) 1995-11-10
ES2169128T3 (es) 2002-07-01
AU715177B2 (en) 2000-01-20
CA2187803C (fr) 1999-09-28
DE69525151T2 (de) 2002-08-14
WO1995028167A1 (fr) 1995-10-26
NO964342L (no) 1996-12-13
DK0755258T3 (da) 2002-05-13
US5759534A (en) 1998-06-02
FI964033A0 (fi) 1996-10-08
JPH09512015A (ja) 1997-12-02
DE69525151D1 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
FI120670B (fi) Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö
US5849285A (en) Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US5958404A (en) Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US8142769B2 (en) Preparation and xenotransplantation of porcine islets
WO2002096203A1 (fr) Differentiation de cellules souches
Scharp et al. Isolating the elusive islet
Lacy et al. Prolongation of islet xenograft survival (rat to mouse)
Cameron et al. Post-thaw viability and functionality of cryopreserved rat fetal brain cells cocultured with Sertoli cells
JP5579270B2 (ja) 膵島と脂肪組織由来幹細胞を利用した膵島移植
US20020065212A1 (en) Methods of treating disease using sertoli cells and allografts or xenografts
Charles et al. Storage and microencapsulation of islets for transplantation
Karl et al. Transplantation of insulin-secreting tissues.
Nakagawara et al. Insulin-releasing activity and successful transplantation of pancreatic islets preserved by tissue culture
Peterson et al. Fetal islet transplantation: implications for diabetes
Peterson et al. Human fetal pancreas transplants
Horaguchi et al. Islet recovery in chronic pancreatitis
Walthall et al. Rodent xenografts of human and porcine fetal tissue
Kojima et al. Culture of the islets of Langerhans for transplantation
Andersson et al. Experimental studies of transplantation and regeneration of endocrine pancreatic cells
Nolan et al. In vitro effects of short-term cortisol exposure on proliferation and apoptosis in the skin epidermis of rainbow trout (Oncorhynchus mykiss Walbaum)
McCullough et al. Human Islet Isolation and Transplantation
Özdamar The Effects Of Long-Term Parenteral Nutrition On Dog Pancreas: An Electron Microscopic Study
KR20000029133A (ko) 췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법
AU2002312125A1 (en) Stem cell differentiation

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120670

Country of ref document: FI

MA Patent expired